The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Partnership with Click Labs Group

4 Sep 2019 07:00

RNS Number : 1151L
mporium Group PLC
04 September 2019
 

04 September 2019

Mporium Group plc

("Mporium" or the "Group")

 

Commercial Partnership with Click Labs Group

Mporium Group plc (AIM: MPM), the technology firm delivering event-driven marketing, is pleased to announce a commercial partnership with Click Labs Group ("Click Labs"), a performance marketing agency specialising in the design, build and deployment of multi-channel lead generation campaigns.

The collaboration will see Mporium deploying its IMPACT technology across Click Labs' core clients to enhance the performance of established and new customer acquisition programmes. In addition, Click Labs will work closely with the existing Mporium Lead Generation division to accelerate revenue growth, focused initially on financial services and claims management clients, prior to further roll out across their portfolio of sports, health, homeware and utilities clients. The Company will receive a share of revenue pursuant to the collaboration.

The first major deployment of this joint offering is scheduled to commence shortly with a leading legal and claims management company in the UK, which the Company believes will endorse its combined offering of IMPACT and the Lead Generation division.

Mporium's Chief Executive, Tom Smith, said:

 

"We are really excited by the commercial partnership with Click Labs which will bring together two highly complementary businesses. We can now offer a business solution to all customers which will drive significant revenue opportunities for both performance marketing and technology licensing. The first deployment of this joint offering will be a powerful proof of concept."

Click Labs Chief Executive, Piers de Grouchy, said:

 

"Mporium's IMPACT technology enables us to trigger our media strategies in perfect synchronisation with market signals. This unique ability to deliver campaigns at the optimal micro moment maximises performance for our partners beyond anything that can be offered by our competition.

 

"This represents a great opportunity for both organisations that we believe will change the performance-based lead generation landscape exponentially."

 

- Ends -

 

Enquiries

 

Mporium:

020 3841 8411

Tom Smith, Chief Executive Officer

finnCap (NOMAD / Joint Broker):

020 7220 0500

Henrik Persson / Kate Bannatyne (Corporate Finance)

Andrew Burdis (Corporate Broking)

 

Novum Securities Limited (Joint Broker):

Colin Rowbury (Corporate Broking)

 

 

 020 7399 9427

Yellow Jersey PR:

020 3004 9512

Sarah Hollins

Joe Burgess

Annabel Atkins

 

Notes to editors

About Mporium

Mporium is a technology company at the forefront of the transformation in digital marketing. Mporium's proprietary technology enables advertisers, to identify and leverage moments when there are significant changes in the levels of consumer engagement.

Based in the UK, Mporium Group plc is quoted on AIM, the junior market of the London Stock Exchange plc.

About Click Labs Group

Click Labs Group is a leading performance based digital agency focussed on the design, build and delivery of end-to-end multi-channel lead generation campaigns.

Based in the UK, Click Labs have delivered over 2000 campaigns for more than 300 brands in 15 markets across a range of verticals spanning automotive, finance, claims management, sports, gaming and healthcare.

www.mporium.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTUORWRKAAKRAR
Date   Source Headline
27th Jun 20087:00 amRNSAHS Meeting
25th Jun 200810:28 amRNSDirector/PDMR Shareholding
24th Jun 200810:23 amRNSResult of Annual General Meet
24th Jun 20087:00 amRNSAGM Statement
16th Jun 20087:30 amRNSTEMPUS study fully enrolled
4th Jun 20087:00 amRNSAnnual Report and Accounts
2nd Jun 20087:00 amRNSUS Marketing Consultant
22nd May 20087:00 amRNSPreliminary Results
12th Mar 20087:00 amRNSAura trial fully enrolled
5th Feb 20087:00 amRNSTEMPUS Trial Update
3rd Dec 20077:00 amRNSInterim Results
16th Oct 20077:00 amRNSTEMPUS trial starts in US
4th Oct 200711:06 amRNSChange of Registered Office
28th Sep 200711:32 amRNSDirector/PDMR Shareholding
17th Aug 20077:00 amRNSAIM Rule 26
16th Jul 200711:29 amRNSResult of AGM
16th Jul 20077:00 amRNSAGM Statement
2nd Jul 20074:13 pmRNSHolding(s) in Company
27th Jun 20077:01 amRNSIHS Scientific Meeting
21st Jun 20075:05 pmRNSAnnual Report and Accounts
13th Jun 20077:02 amRNSPreliminary Results
7th Jun 20077:02 amRNSAHS Scientific Meeting
1st Jun 20078:30 amRNSTotal Voting Rights
18th May 20079:20 amRNSAdditional Listing
30th Apr 20076:22 pmRNSHolding(s) in Company
30th Apr 200712:16 pmRNSTotal Voting Rights
11th Apr 20074:39 pmRNSConversion of Loan Note
2nd Apr 20073:27 pmRNSHolding(s) in Company
2nd Apr 20072:55 pmRNSHolding(s) in Company
2nd Apr 20071:26 pmRNSDirector/PDMR Shareholding
30th Mar 20079:32 amRNSTotal Voting Rights
27th Mar 20077:01 amRNSBoard Appointments
26th Mar 200710:31 amRNSResult of EGM
2nd Mar 20077:30 amRNSGPB17m fundraising
9th Jan 20077:01 amRNSPositive Tonabersat Study
20th Dec 20065:43 pmRNSTotal Voting Rights
1st Dec 20067:01 amRNSInterim Results
17th Nov 20067:01 amRNSPlacing
25th Oct 200610:20 amRNSResult of AGM
25th Oct 20067:01 amRNSAGM Statement
27th Sep 20067:00 amRNSNIH Collaboration
20th Sep 20067:02 amRNSPreliminary Results
7th Sep 20067:00 amRNSAdditional Indications
15th Aug 200611:37 amRNSNotification of Interests
20th Jun 20067:00 amRNSStart of Phase II Trial
24th May 20067:01 amRNSUCLA Collaboration
21st Mar 20067:00 amRNSStart of Phase II Trial
8th Mar 20067:03 amRNSChange of Adviser
13th Jan 20067:00 amPRNRe Agreement
8th Dec 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.